Abecma — idecabtagene vicleucel
Named-patient access overview. Abecma is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Abecma
Abecma (idecabtagene vicleucel) is manufactured by BMS/2seventy and indicated for Multiple myeloma. It is a CAR-T (BCMA) approved by the US FDA in 2021 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Abecma
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Abecma for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Abecma is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Abecma in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Abecma in BahrainNamed-patient access, timeline, and regulatory notes
Abecma in EgyptNamed-patient access, timeline, and regulatory notes
Abecma in IndiaNamed-patient access, timeline, and regulatory notes
Abecma in JordanNamed-patient access, timeline, and regulatory notes
Abecma in KuwaitNamed-patient access, timeline, and regulatory notes
Abecma in PakistanNamed-patient access, timeline, and regulatory notes
Abecma in QatarNamed-patient access, timeline, and regulatory notes
Abecma in TurkeyNamed-patient access, timeline, and regulatory notes
Start a request for Abecma
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.